Absence of acute cocaine interactions with the MAO-B inhibitor selegiline

Kathleen A. Haberny, Sharon L. Walsh, David H. Ginn, Jeffery N. Wilkins, Jane E. Garner, David Setoda, George E. Bigelow

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalDrug and alcohol dependence
Issue number1
StatePublished - Jul 1995


  • Cardiovascular
  • Cocaine
  • Safety
  • Selegiline
  • Subjective
  • l-Deprenyl

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Absence of acute cocaine interactions with the MAO-B inhibitor selegiline'. Together they form a unique fingerprint.

Cite this